APA (7th ed.) Citation

Weir, M. R., Ashton, V., Moore, K. T., Shrivastava, S., Peterson, E. D., & Ammann, E. M. (2020). Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. The American heart journal, 223, 3-11. https://doi.org/10.1016/j.ahj.2020.01.010

Chicago Style (17th ed.) Citation

Weir, Matthew R., Veronica Ashton, Kenneth T. Moore, Shubham Shrivastava, Eric D. Peterson, and Eric M. Ammann. "Rivaroxaban Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and Stage IV-V Chronic Kidney Disease." The American Heart Journal 223 (2020): 3-11. https://doi.org/10.1016/j.ahj.2020.01.010.

MLA (9th ed.) Citation

Weir, Matthew R., et al. "Rivaroxaban Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and Stage IV-V Chronic Kidney Disease." The American Heart Journal, vol. 223, 2020, pp. 3-11, https://doi.org/10.1016/j.ahj.2020.01.010.